Ipamorelin
Regulatory
Legal Status in 2026
Compounding restricted under the FDA 503A bulk-substance list.
Federal law restricts compounding of this compound. For compounds whose FDA-declared shortage has resolved, Section 503B bulk compounding rights have ended; Section 503A compounding remains possible only with a documented patient-specific clinical justification (a verified allergy to an inactive ingredient, or a strength the manufacturer does not make, not cost or convenience). For compounds affirmatively excluded by the FDA's Pharmacy Compounding Advisory Committee, compounding is not permitted under the bulk-substance list. The FDA-approved product (where one exists) is the appropriate default.
About
About Ipamorelin
A synthetic pentapeptide growth hormone secretagogue, ipamorelin selectively stimulates pituitary release of growth hormone by mimicking ghrelin and binding to the growth hormone secretagogue receptor (GHS-R). Unlike earlier secretagogues, it demonstrates high selectivity for GH release with minimal effect on cortisol, prolactin, or appetite-regulating hormones. Research applications have focused on its potential use in growth hormone deficiency, age-related muscle loss, and bone metabolism studies.
Science
Mechanism of Action
Ipamorelin binds to the GHSR-1a (ghrelin receptor) on anterior pituitary somatotrophs with high affinity and selectivity. Receptor activation increases intracellular calcium and stimulates GH secretion. Its selectivity for the GHSR-1a over other GPCR receptors explains its minimal effect on cortisol and prolactin compared to GHRP-2 and GHRP-6, which have broader receptor activity.
Dosing
Typical Protocol
100–300 mcg subcutaneously 1–3 times daily, typically before bed and sometimes pre-workout. Commonly combined with CJC-1295 without DAC (Modified GRF 1-29) at matching doses. Protocols run for 3–6 month cycles with periodic IGF-1 monitoring. Administered subcutaneously in the abdomen or thigh.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Evidence
Evidence Tier
Evidence from randomized controlled trials (RCTs) or large observational studies in humans. This is the gold standard: effects have been measured in controlled conditions and results are peer-reviewed and reproducible.
Providers advertising Ipamorelin
A Ipamorelin mention is not a fulfillment check. Confirm with the provider exactly what is being dispensed and which pharmacy fills it.
Marek HealthMen's Health Telehealth · Peptide Therapy · LegitScript Certified
LifeForceMen's Health Telehealth · Peptide Therapy · LegitScript Certified
Olympia Pharmacy503A/503B Compounding Pharmacy · GLP-1 Specialist · PCAB & LegitScript
Hone HealthMen's Health Telehealth · GLP-1 Specialist · LegitScript Certified
Belmar PharmacyCompounding Pharmacy · TRT & HRT · PCAB Accredited
NRG ClinicMen's Health Telehealth · GLP-1 Specialist
FagronCompounding Pharmacy
PeterMDMen's Health Telehealth · GLP-1 Specialist
Defy MedicalMen's Health Telehealth · GLP-1 Specialist
Medical Health InstituteMen's Health Telehealth · Specialty Focused
Fountain LifeConcierge Clinic · Peptide Therapy
Highland LongevityClinic & Medical Practice · GLP-1 Specialist
Compound comparisons
Compare Ipamorelin
Ipamorelin set against other compounds people weigh it against.
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.